Actively Recruiting
Evaluating Autologous Bone Marrow Aspirate Concentrate Added to Core Decompression for Early Osteonecrosis of the Femoral Head
Led by Johns Hopkins University · Updated on 2026-09-17
192
Participants Needed
10
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Osteonecrosis of the femoral head ONFH is a painful condition where bone cells in the hip bone die, often leading to the collapse of the bone and arthritis, especially in younger adults. This trial compares two treatments for early-stage ONFH to see if adding autologous bone marrow aspirate concentrate BMAC to core decompression CD improves outcomes. There is no current consensus on the best joint-preserving procedures, so this study aims to provide clearer evidence. Participants will be randomly assigned to receive either core decompression alone with a sham bone marrow aspiration or core decompression combined with an injection of concentrated autologous bone marrow aspirate into the femoral head. The procedures follow standardized protocols, and the study includes laboratory analysis of bone marrow samples to explore biological factors related to treatment success. Throughout the study, participants will have clinical evaluations before surgery and at 6 months via telemedicine, 1 year, and 2 years after surgery. Assessments include radiographs, MRIs, and questionnaires about pain and function. Researchers will measure radiological progression to advanced disease stages, pain changes, and time to treatment failure. The study will continue until 2029, with a focus on preserving the femoral head and improving patient outcomes.
CONDITIONS
Brief Title
Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis
Research Team
L
Lynne C Jones, PhD
S
Stuart Goodman, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here